RVMD Stock Performance, Insider Transaction and News

RVMD - Revolution Medicines, Inc.

Market Cap	3.48B	P/E	-	EPS this Y	17.40%	Ern Qtrly Grth	-
Income	-436.37M	Forward P/E	-10.18	EPS next Y	-7.50%	50D Avg Chg	25.00%
Sales	11.58M	PEG	-	EPS past 5Y	-	200D Avg Chg	36.00%
Dividend	N/A	Price/Book	3.66	EPS next 5Y	-	52W High Chg	-
Recommedations	1.50	Quick Ratio	12.89	Shares Outstanding	164.69M	52W Low Chg	92.00%
Insider Own	2.46%	ROA	-20.08%	Shares Float	160.84M	Beta	1.54
Inst Own	96.10%	ROE	-34.75%	Shares Shorted/Prior	12.49M/16.40M	Price	32.78
Gross Margin	-	Profit Margin	-	Avg. Volume	1,021,824	Target Price	41.58
Oper. Margin	-20,819.81%	Earnings Date	May 6	Volume	3,063,320	Change	4.06%

Healthcare | Biotechnology | United States

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc. News

04/09/24	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
04/08/24	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
04/04/24	Revolution Medicines to Participate in Upcoming Investor Conferences
03/28/24	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
02/28/24	Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript
02/28/24	Revolution Medicines Full Year 2023 Earnings: Misses Expectations
02/27/24	Q4 2023 Revolution Medicines Inc Earnings Call
05:20 PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
04:32 PM	Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress
04:05 PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
02/20/24	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
01/17/24	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
01/05/24	Carnival upgraded, PayPal downgraded: Wall Street's top analyst calls
01/04/24	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
12/21/23	Revolution Medicines Inc Insider Sells Shares
12/15/23	Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
12/10/23	Insider Sell Alert: COO Margaret Horn Sells 5,000 Shares of Revolution Medicines Inc (RVMD)
11/17/23	A great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who own 74% must be happy
11/16/23	3 Biotech Stocks That Could Boom or Bust by 2025
11/09/23	Revolution Medicines Completes Acquisition of EQRx

RVMD Chatroom

markovb343 Posted - 9 hours ago

$RVMD we held 34 here REALLY nicely even as the rest of XBI was getting murdered. There's something brewing.

EmSol Posted - 9 hours ago

$RVMD are we at $200 yet

Irish_lass Posted - 3 days ago

$RVMD

Irish_lass Posted - 4 days ago

$RVMD “In recent years, drugs have been approved for treating cancers caused by KRAS-G12C, a common form of the KRAS mutation. But the effectiveness of these drugs, which target only the inactive state of mutant KRAS, is often short-lived. Now a team led by researchers from MSK has taken a cue from nature: Inspired by drugs based on molecules found in plants, fungi, and other living organisms, they identified a compound from Streptomyces bacteria and modified it to target the active state of mutant KRAS, a state that historically has proved very difficult to target by conventional methods. MSK physician-scientist Piro Lito, MD, PhD, collaborated on the research with the company Revolution Medicines. By modifying the shape of the natural product, the team was able to sculpt the surface in a way that it could recognize the active version of mutant KRAS, thus preventing its cancer-causing activity.” https://www.mskcc.org/news/msk-research-highlights-august-24-2023

Irish_lass Posted - 4 days ago

$RVMD https://www.cuimc.columbia.edu/news/opening-new-front-against-pancreatic-cancer

Mistorab Posted - 4 days ago

$RVMD my 80yo has stage 4 lung CA that spread. No other options left. Went to Sloan Kettering in NYC. After 8 weeks of therapy, every single tumor has shrunk, 2 can no longer be seen. Unbelievable. All in

Irish_lass Posted - 4 days ago

$RVMD Ought to be another interesting week.

FlynancialAnalyst Posted - 1 week ago

$RVMD $5.94B mc $XBI name with a 3yr high wkly close on volume into key $40 level 95.94% institutionally owned, 7.46% short float, rapidly declining for over 2 years! #CoverOrPerish... ATHs on deck imo TrendEdge.app/asset/RVMD

insiderbuyingselling Posted - 2 weeks ago

$RVMD new insider selling: 17500 shares. http://insiderbuyingselling.com/?t=RVMD

Quantumup Posted - 2 weeks ago

Needham⬆️ $RVMD $46 was $36/Buy~after +VE preclin data in G13X/Q61X supported by clin activity in 3 pts w/ non-G12C mutations in PDAC/CRC/melanoma — the preclin data support that the combo of RMC-6236/RMC-6291 can generate meaningful improvement in durability +⬆️response rates:

Quantumup Posted - 2 weeks ago

Oppenheimer⬆️ $RVMD $45 was $43/OP RVMD provided broad updates@ #AACR24, along w/ notable pubs in Nature and Cancer Discovery/OPY was most interested in the pres/pub on RMC-6236, which further supports devt plan. OPY anticipates a data-heavy 2H that should drive add'l upside:

AnaChart Posted - 2 weeks ago

$RVMD https://anachart.com/wp-content/uploads/ana_temp/1712919704_soc-img.jpg

Theryanzamo Posted - 2 weeks ago

$RVMD who’s been holding with me!!?

Irish_lass Posted - 2 weeks ago

$RVMD Well hallelujah 😂

M1cha3lP Posted - 2 weeks ago

$RVMD Yes, run baby run!

EmSol Posted - 2 weeks ago

$RVMD $60 next resistance

EmSol Posted - 2 weeks ago

$RVMD inflation? What is that? We don’t care going to ATH at $60

M1cha3lP Posted - 2 weeks ago

$RVMD Looking good. :)

M1cha3lP Posted - 2 weeks ago

$RVMD Are we going to break yesterdays high now???

EmSol Posted - 2 weeks ago

$RVMD are we at $100 yet

victorcastro Posted - 2 weeks ago

$FCFS $PTON $RDDT $RVMD $WBA

JackDarwin Posted - 2 weeks ago

$RVMD Nice Bullish Gap Up Formed At Uptrend.

coloradoriley Posted - 2 weeks ago

Trends with No Friends, 4-10-2024 New 52-Week Lows led New Highs — 52 vs. 31. Walgreens Boots Alliance $WBA is the worst of the worst. Reddit $RDDT and Peloton $PTON are notable new lows. Revolution Medicines $RVMD is the best of the best. Alpine Immune Sciences and FirstCash Holdings $FCFS are notable new highs. Click the link to view today's 52W highs and lows sorted by followers on @Stocktwits https://nofriends.beehiiv.com/p/4-10-2024 cc @howardlindzon

Irish_lass Posted - 2 weeks ago

$RVMD

Irish_lass Posted - 2 weeks ago

$RVMD

Irish_lass Posted - 2 weeks ago

$RVMD “The discovery of RMC-6236 allowed for the first-ever therapeutic evaluation of targeted concurrent inhibition of both canonical mutant and wild-type RAS-GTP (RAS(ON)) in RAS-driven cancers. The RMC-6236 clinical data that we have shared not only provide platform validation of our tri-complex inhibitor approach, but also refute the dogma that one could not induce anti-tumor activity by broad inhibition of multiple RAS variants, including wild-type RAS, at doses that would be well tolerated,” said Steve Kelsey, M.D., president, research and development of Revolution Medicines. “

_StockTrader Posted - 2 weeks ago

Real-Time Stock Data $RVMD Price: 35.62 Volume: 3124082 Market Cap: 5836613120 PE Ratio: -10.213256 Powered by: AITX

Run2Runn2Runnn Posted - 2 weeks ago

$ADIL $RVMD Thanks 🙏 both runners!!

Run2Runn2Runnn Posted - 2 weeks ago

$ADIL $RVMD made the day!!

RockyTSTH Posted - 2 weeks ago

$RVMD Revolution Medicines shares are trading higher. The company recently announced the publication of a research paper on RMC-6236 in Cancer Discovery.

Analyst Ratings

Oppenheimer	Outperform	Apr 12, 24
Needham	Buy	Apr 12, 24
Raymond James	Strong Buy	Apr 10, 24
Needham	Buy	Apr 8, 24
Piper Sandler	Overweight	Mar 11, 24
HC Wainwright & Co.	Buy	Mar 8, 24
Morgan Stanley	Equal-Weight	Mar 8, 24
Wedbush	Outperform	Feb 27, 24
Raymond James	Outperform	Jan 16, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Anders Jack	Chief Financial Offi.. Chief Financial Officer	Dec 18	Sell	25.9018	1,775	45,976	76,416	12/20/23
GOLDSMITH MARK A	See Remarks See Remarks	Dec 18	Sell	25.9018	8,165	211,488	376,167	12/20/23
Cislini Jeff	General Counsel General Counsel	Dec 18	Sell	25.9017	1,229	31,833	37,284	12/20/23
Kelsey Stephen Michael	See Remarks See Remarks	Dec 18	Sell	25.9016	2,088	54,083	271,633	12/20/23
Horn Margaret A	Chief Operating Offi.. Chief Operating Officer	Dec 15	Sell	26.27	7,993	209,976	101,467	12/19/23
Horn Margaret A	Chief Operating Offi.. Chief Operating Officer	Dec 15	Option	4.09	5,000	20,450	109,460	12/19/23
Cislini Jeff	General Counsel General Counsel	Nov 20	Sell	21.6966	1,500	32,545	38,513	11/20/23
Horn Margaret A	Chief Operating Offi.. Chief Operating Officer	Oct 25	Option	0.54	7,500	4,050	104,460	10/25/23
GOLDSMITH MARK A	See Remarks See Remarks	Oct 24	Option	0.49	35,000	17,150	384,332	10/24/23
Anders Jack	Chief Financial Offi.. Chief Financial Officer	Oct 23	Option	3.39	24,524	83,136	78,191	10/23/23
Cislini Jeff	General Counsel General Counsel	Sep 28	Sell	28.58	2,000	57,160	40,013	10/02/23
GOLDSMITH MARK A	See Remarks See Remarks	Sep 01	Option	0.83	30,000	24,900	387,386	09/06/23
GOLDSMITH MARK A	See Remarks See Remarks	Sep 01	Sell	35.04	40,000	1,401,600	35,424	09/06/23
Weber Barbara	Director Director	Sep 01	Sell	35.07	15,000	526,050	15,825	09/06/23
Weber Barbara	Director Director	Sep 01	Option	2.93	15,000	43,950	30,825	09/06/23
Anders Jack	Chief Financial Offi.. Chief Financial Officer	Sep 01	Sell	35.05	20,000	701,000	55,094	09/06/23
Anders Jack	Chief Financial Offi.. Chief Financial Officer	Sep 01	Option	2.68	20,000	53,600	75,094	09/06/23
Cislini Jeff	General Counsel General Counsel	Jul 31	Sell	26.02	1,500	39,030	43,227	08/01/23
Horn Margaret A	See Remarks See Remarks	Mar 17	Sell	21.78	1,230	26,789	100,062	03/21/23
Anders Jack	Chief Financial Offi.. Chief Financial Officer	Mar 17	Sell	21.78	665	14,484	55,233	03/21/23
Kelsey Stephen Michael	See Remarks See Remarks	Mar 17	Sell	21.78	1,230	26,789	326,369	03/21/23
Wang Xiaolin	See Remarks See Remarks	Mar 17	Sell	21.78	714	15,551	58,813	03/21/23
Schroeder Thilo	Director Director	Mar 07	Buy	21.32	650,000	13,858,000	1,553,134	03/10/23
GOLDSMITH MARK A	See Remarks See Remarks	Feb 22	Option	0.49	45,000	22,050	251,872	02/23/23
Horn Margaret A	Chief Operating Offi.. Chief Operating Officer	Oct 31	Sell	20.4053	17,767	362,541	17,767	11/02/22
Wang Xiaolin	See Remarks See Remarks	Sep 19	Sell	19.0426	735	13,996	31,235	09/21/22
Kelsey Stephen Michael	See Remarks See Remarks	Sep 19	Sell	19.0426	1,267	24,127	288,819	09/21/22
Horn Margaret A	See Remarks See Remarks	Sep 19	Sell	19.0426	1,267	24,127	62,512	09/21/22
Anders Jack	Chief Financial Offi.. Chief Financial Officer	Sep 19	Sell	19.0426	449	8,550	29,956	09/21/22
GOLDSMITH MARK A	See Remarks See Remarks	Aug 11	Option	0.49	10,000	4,900	206,872	08/15/22
GOLDSMITH MARK A	See Remarks See Remarks	Aug 09	Option	0.49	10,336	5,065	196,872	08/10/22
Schroeder Thilo	Director Director	Jul 22	Buy	20.00	250,000	5,000,000	1,221,315	07/26/22
Kim Lorence H.	Director Director	Jul 22	Buy	20.00	50,000	1,000,000	60,500	07/25/22
Wang Xiaolin	See Remarks See Remarks	Jun 17	Sell	17.7495	665	11,803	31,970	06/22/22
Kelsey Stephen Michael	See Remarks See Remarks	Jun 17	Sell	17.7495	1,145	20,323	290,086	06/22/22
Horn Margaret A	See Remarks See Remarks	Jun 17	Sell	17.7495	1,145	20,323	63,779	06/22/22
Anders Jack	See Remarks See Remarks	Jun 17	Sell	17.7495	406	7,206	20,405	06/22/22
Third Rock Ventures III, L.P.	10% Owner 10% Owner	Jun 08	Sell	20.25	419,901	8,502,995	5,104,130	06/10/22
Exter Neil	Director Director	Jun 08	Sell	0.00				06/10/22
Schroeder Thilo	Director Director	Mar 25	Buy	24.85	42,725	1,061,716	971,315	03/29/22
Schroeder Thilo	Director Director	Mar 22	Buy	23.48	232,364	5,455,907	928,590	03/24/22
Schroeder Thilo	Director Director	Mar 17	Buy	20.08	168,051	3,374,464	696,226	03/21/22
Horn Margaret A	See Remarks See Remarks	Mar 17	Sell	18.6145	321	5,975	63,987	03/21/22
Kelsey Stephen Michael	See Remarks See Remarks	Mar 17	Sell	18.6162	321	5,976	290,294	03/21/22
Wang Xiaolin	See Remarks See Remarks	Mar 17	Sell	18.6142	240	4,467	31,698	03/21/22
GOLDSMITH MARK A	See Remarks See Remarks	Mar 17	Sell	18.6141	1,023	19,042	185,599	03/21/22
Anders Jack	See Remarks See Remarks	Mar 17	Sell	18.6162	159	2,960	19,875	03/21/22
Schroeder Thilo	Director Director	Mar 10	Buy	20.91	43,510	909,794	528,175	03/14/22
Schroeder Thilo	Director Director	Mar 07	Buy	19.14	246,438	4,716,823	484,665	03/09/22
Schroeder Thilo	Director Director	Feb 18	Buy	23.17	1,088,227	25,214,220	238,227	03/04/22